{"title":"Optimal dose selection in phase I/II dose finding trial with contextual bandits: a case study and practical recommendations.","authors":"Jixian Wang, Ram Tiwari","doi":"10.1080/10543406.2025.2469877","DOIUrl":null,"url":null,"abstract":"<p><p>Dose selection is a key decision to make in the early phase of drug development. Classical phase I/II dose-finding trials randomly assign a few doses and select the best among them. Response-adaptive assignment designs are more efficient but are still far from optimal. Recently, some researchers used machine learning (ML) methods such as contextual bandits (CB) to find the \"optimal\" dose and to investigate the asymptotic properties of the methods. We present a case study for oncology phase I/II dose-finding trial designs using Thompson sampling and Bayesian bootstrap for CB with either modeling clinical utility directly or jointly modeling efficacy and safety. We focus on practical questions such as the number of interim analyses to conduct and whether we should model the utility directly, jointly model efficacy and safety which compose the utility, or use a model independent approach such as multi-armed bandits, but not for a specific compound or tumor type. We also consider how to use weak informative prior information. We conducted an extensive simulation study and compared different combinations of design settings and modeling methods, under several feasible scenarios of the dose-response relationship. Based on simulation results, we make practical recommendations for the use of the proposed ML approach for phase I/II dose-finding trial designs.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-27"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2469877","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Dose selection is a key decision to make in the early phase of drug development. Classical phase I/II dose-finding trials randomly assign a few doses and select the best among them. Response-adaptive assignment designs are more efficient but are still far from optimal. Recently, some researchers used machine learning (ML) methods such as contextual bandits (CB) to find the "optimal" dose and to investigate the asymptotic properties of the methods. We present a case study for oncology phase I/II dose-finding trial designs using Thompson sampling and Bayesian bootstrap for CB with either modeling clinical utility directly or jointly modeling efficacy and safety. We focus on practical questions such as the number of interim analyses to conduct and whether we should model the utility directly, jointly model efficacy and safety which compose the utility, or use a model independent approach such as multi-armed bandits, but not for a specific compound or tumor type. We also consider how to use weak informative prior information. We conducted an extensive simulation study and compared different combinations of design settings and modeling methods, under several feasible scenarios of the dose-response relationship. Based on simulation results, we make practical recommendations for the use of the proposed ML approach for phase I/II dose-finding trial designs.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.